President Donald Trump rolled out "The Great Healthcare Plan" on Thursday, and if you're wondering what's actually in it, the headline feature is a direct assault on pharmacy benefit managers. Not a subtle policy tweak, mind you, but an explicit targeting of what Trump calls "kickbacks" that these middlemen collect.

The plan is ambitious: slash drug prices, cut insurance premiums, and fundamentally reshape how money flows through the American healthcare system. And according to experts who've been studying this industry, Trump might actually be onto something here.

Understanding the Middleman Tax

At the heart of the proposal is a mandate to eliminate kickback payments from pharmacy benefit managers to large brokerage middlemen. The White House isn't mincing words, either. These payments "deceptively raise the cost of health insurance," according to the administration's analysis.

Trump's pitch is straightforward: stop sending subsidies to massive insurance companies and redirect that money directly to Americans who qualify. "The big insurance companies lose and the people of our country win," Trump said during his announcement, promising to secure "massive discounts" on prescription medications.

It sounds like standard political rhetoric, except industry insiders are essentially confirming that yes, this is exactly how the system works.

The "Pay for Play" Problem

Warris Bokhari, founder of Claimable and a healthcare expert, laid out the PBM business model in stark terms during a January 12 discussion on The Real Eisman Playbook. He called it a "pay for play" system where PBMs essentially construct drug formularies based on rebates rather than what actually works best for patients.

Think of it like this: if you're a drug manufacturer and you want access to, say, a third of the insured population in America, the PBM tells you what size rebate you need to pay. Bokhari described this fee structure as a "vig," using the term bookies apply to their cut of gambling action. It's essentially a toll for market access.

Here's the kicker: Bokhari estimates that manufacturers would price drugs "5x lower" if PBMs were simply removed from the equation. That's not a marginal improvement. That's the difference between a $500 medication and a $100 one.

Plain English, Please

Beyond the pricing mechanics, Trump's plan demands something called "Plain-English Insurance" standards. Insurers would be required to publish rate and coverage comparisons without burying customers in industry jargon.

This matters more than it might sound. Experts have warned that insurance companies deliberately leave terms like "valid claims" undefined, creating wiggle room to deny coverage when it's inconvenient. The administration is calling for "unprecedented accountability," which sets up what's likely to be a significant fight with the healthcare lobby.

Market Implications

So who stands to win or lose if these reforms actually happen? The major PBM operators are the obvious pressure points. CVS Health Corp. (CVS) is up 1.54% year-to-date and has climbed 56.58% over the past year, though much of that reflects broader market dynamics. Cigna Group (CI) is down 0.42% this year and 1.08% over the past twelve months. UnitedHealth Group Inc. (UNH) has gained 0.76% year-to-date but is down 33.61% over the past year, reflecting ongoing scrutiny of the health insurance sector.

For investors trying to position around potential healthcare reforms, pharmaceutical ETFs offer broader exposure. The VanEck Pharmaceutical ETF (PPH) is up 1.27% year-to-date with a 21.46% gain over the past year. The iShares US Pharmaceuticals ETF (IHE) has climbed 1.36% this year and 28.20% over twelve months. The Invesco Pharmaceuticals ETF (PJP) is up 0.36% year-to-date with a 26.32% annual return.

The SPDR S&P Pharmaceuticals ETF (XPH) leads recent performance with a 1.49% year-to-date gain and 32.55% six-month return. For those interested in international exposure, the KraneShares MSCI All China Health Care Index ETF (KURE) has surged 9.55% this year and 40.90% over the past year. The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is up 1.12% year-to-date with a 23.49% annual gain, while the leveraged Direxion Daily Pharmaceutical & Medical (PILL) has jumped 2.98% this year with a remarkable 108.08% six-month return.

What Happens Next

The question now is whether Trump can actually execute this plan. The healthcare lobby is one of the most powerful in Washington, and PBMs have spent years building relationships and defending their business model as necessary for managing drug costs.

But the administration has expert validation for its core diagnosis of the problem, and the "kickback" framing is politically potent. Whether that translates into actual reform or gets diluted through the legislative process remains to be seen. For now, investors and patients alike are watching to see if this healthcare overhaul moves beyond the announcement stage.